Ep 55: VIBE Intro - Give Us Your Feedback

12/12/24 • 3 min

In this episode we are calling VIBE - Voicing Interesting Bits from Everyone - we want to hear from YOU!

We've opened an email address to field your questions, concerns, feedback and input.

While we cannot answer specific patient case questions, this is a great forum to clarify any questions around the data. Our plan is to record an episode discussing the questions we receive.

[email protected]

In this episode we are calling VIBE - Voicing Interesting Bits from Everyone - we want to hear from YOU!

We've opened an email address to field your questions, concerns, feedback and input.

While we cannot answer specific patient case questions, this is a great forum to clarify any questions around the data. Our plan is to record an episode discussing the questions we receive.

[email protected]

Previous Episode

Ep 54: All things MSLT with Mark Faries

Summary

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin welcome surgical oncologist Mark Faries to discuss the evolution of surgical practices in melanoma, particularly focusing on sentinel lymph node biopsy and the implications of recent clinical trials. They explore the historical context of lymph node surgeries, the significance of nomograms in predicting patient outcomes, and the latest NCCN guidelines regarding clinic l stage II melanoma. They also delve into the emerging role of neoadjuvant therapies and the planned MSLT-3 trial, exploring the balance between effective treatment and minimizing surgical interventions. The discussion highlights the importance of staging information and the potential immunosuppressive effects of surgery, concluding with reflections on the collaborative nature of oncology care.

Takeaways

The significance and historical context of sentinel lymph node biopsy in melanoma treatment.
NCCN recommendations are evolving regarding sentinel lymph node biopsies.
Neoadjuvant therapies are changing the surgical landscape.
MSLT-3 aims to explore less invasive surgical options.
Surgery has immunosuppressive effects that need consideration.
Accurate staging information is a factor in decisions about treatment.
Collaboration between surgical and medical oncologists is fun!

Keywords

melanoma, surgical oncology, lymph nodes, sentinel lymph node biopsy, MSLT trials, adjuvant therapy, nomograms, NCCN guidelines, neoadjuvant therapy, immune suppression

Titles

Navigating Melanoma: Insights from Surgical Oncology

The Evolution of Sentinel Lymph Node Surgery

Sound Bites

"No tumor is resistant to formaldehyde."

"Surgery is the gold standard."

"We need that staging information."

Chapters

00:00 Introduction and Welcome to Special Guest, Mark Faries

06:06 The Evolution of Lymph Node Surgery

09:07 MSLT Trials: Insights and Outcomes

11:59 Current Practices in Sentinel Lymph Node Biopsy

15:02 Adjuvant Therapy and Its Implications

21:09 NCCN Guidelines and Clinical Stage II Disease

24:19 MSLT-3: A New Era in Melanoma Surgery

26:52 The Role of Immune Suppression with Surgery

Next Episode

Ep 56: Best of 2024: ASCO

Summary

Verbalizing punctuation for laughs...background wood noises ... and out of office replies get things started.

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel record their first in a series of "Best of 2024" and review highlights from the ASCO Annual Meeting. They focus on 4 significant trials: NADINA, COMBI-AD, KEYNOTE 942, and RELATIVITY 048.

James & Sapna discuss the implications of these studies on the melanoma landscape, the importance of long-term follow-up data, and share some light-hearted moments about out-of-office messages.

Keywords

ASCO 2024, melanoma, NADINA trial, neoantigen therapy, checkpoint blockade, out of office messages, long-term follow-up, immunotherapy

Takeaways

Out-of-office messages can be creative and memorable.

The NADINA trial showed a high major pathologic response rate of 60%.

Patient inclusion and trial design in clinical trials can critically affect outcomes (COMBI-AD).

The KEYNOTE 942 trial demonstrated encouraging trends for overall survival.

Triplet checkpoint blockade shows promising PFS results (RELATIVITY 048).

Titles

ASCO 2024 Highlights: Melanoma Trials Reviewed

NADINA, COMBI-AD, KN 942, RELA 048

Chapters